These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31188813)

  • 1. Toxicities of checkpoint inhibitors: causes and management.
    Postow MA
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 3. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicities associated with checkpoint inhibitors-an overview.
    Spiers L; Coupe N; Payne M
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decade of immune-checkpoint inhibitors in cancer therapy.
    Robert C
    Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management.
    Grover S; Rahma OE; Hashemi N; Lim RM
    Am Soc Clin Oncol Educ Book; 2018 May; 38():13-19. PubMed ID: 30231401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy in patients with preexisting autoimmune disorders.
    Donia M; Pedersen M; Svane IM
    Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 11. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
    Chow LQ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    Dhariwal R; Pindoria N; Dasgupta P; Khan MS
    BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of PD-1/PD-L1 Inhibitor-Induced Dermatitis Resolves Concomitant Eruptive Keratoacanthomas.
    Crow LD; Perkins I; Twigg AR; Fassett MS; LeBoit PE; Berger TG; Khodosh R
    JAMA Dermatol; 2020 May; 156(5):598-600. PubMed ID: 32211828
    [No Abstract]   [Full Text] [Related]  

  • 15. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer.
    Brahmer JR
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):165-7. PubMed ID: 27058029
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quality of life in immune checkpoint inhibitors trials].
    Coquan E; Joly F
    Bull Cancer; 2020; 107(7-8):830-842. PubMed ID: 32758364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Checkpoint inhibitors neurological side effects].
    Suay G; Bataller L
    Rev Neurol; 2019 Apr; 68(7):301-311. PubMed ID: 30906980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis.
    Sorotsky H; Hogg D; Amir E; Araujo DV
    JAMA Netw Open; 2019 Nov; 2(11):e1914816. PubMed ID: 31702796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
    Daxini A; Cronin K; Sreih AG
    Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.